Selank nasal spray: the route, and the evidence behind it

Most peptides sold as sprays were never tested that way, but Selank nasal spray is the exception, because intranasal is its registered clinical route. The catch is where that evidence originates, and where it stops.

Why the nasal route is not a marketing choice here

Nearly every peptide sold as a nasal spray reached that format the same way: a supplier took a powder meant for injection and put it in a bottle with an atomizer. Selank did not. The Russian Ministry of Health registered it in 2009 as a nasal formulation for generalized anxiety disorder, and the clinical work that supported the registration used the same route.

That is genuinely unusual, and it is the strongest single thing that can be said for a Selank spray. It also carries a distinction the market blurs: the registered Russian product is a metered nasal solution manufactured to pharmaceutical specification. Research-use lyophilized powder that a buyer reconstitutes into a spray bottle is a different product, made under different controls, and the Russian safety record attaches to the former.

The compound itself is a 7-residue peptide, Thr-Lys-Pro-Arg-Pro-Gly-Pro. The first four residues are tuftsin, an immune-signaling fragment released from immunoglobulin G; the Pro-Gly-Pro tail is a stabilizing addition that slows enzymatic breakdown. Selank was developed at Russian state institutes, and that origin explains both the strengths and the gaps in what follows.

What the Russian clinical work reports

The Russian record on Selank in anxiety runs from the 1990s and is largely published in Russian-language journals. Two entries in it are indexed and readable in English abstract:

• The 2008 anxiolytic report. Zozulya and colleagues reported on Selank in generalized anxiety disorder and neurasthenia, which is the study most often cited as the basis for the registration.
• The 2015 add-on study. Medvedev and colleagues compared phenazepam alone in 30 patients against phenazepam plus Selank in 40 patients with anxiety-phobic, hypochondriac and somatoform disorders, scored on HDRS, CGI and Spielberger scales. The combination reached its effect earlier and reduced the side effects of the benzodiazepine — sedation, attention and memory impairment, asthenia — both during treatment and after withdrawal.

Read that second study carefully, because it is often described as showing Selank works for anxiety. What it was designed to show is that Selank added to a benzodiazepine improved on the benzodiazepine alone, in 70 patients total, in an open comparison. That is a real clinical observation and a long way from a placebo-controlled efficacy trial.

Selank

Tuftsin analog7 aaN-acetylated

The same heptapeptide studied across the Russian clinical and preclinical work cited here, supplied as lyophilized powder with a certificate of analysis matched to the lot.

Shop Selank

The one Western human study used the nose too

The most methodologically transparent human study of Selank is a brain-imaging experiment rather than a clinical trial. Panikratova and colleagues scanned 52 healthy adults in a placebo-controlled three-way design comparing Selank, Semax and placebo, with resting-state functional MRI taken before dosing and again at 5 and 20 minutes after intranasal administration.

The reported finding was a change in functional connectivity between the right amygdala and right temporal cortical regions — the network a candidate anxiolytic would be expected to touch — within 20 minutes of a nasal dose.

This is the best evidence that a nasal dose reaches the brain and does something measurable there, and it is worth taking seriously for exactly that. It is not evidence of symptom relief. The participants were healthy, the outcome was a connectivity biomarker rather than an anxiety score, and the observation window was twenty minutes.

The mechanism work, and what it rests on

The proposed mechanism is allosteric modulation rather than direct agonism. A radioligand binding study reported that Selank affects GABA binding as a positive allosteric modulator, and that its combined action with benzodiazepines is not additive — Selank could block the modulatory activity of diazepam and olanzapine, which the authors read as partly overlapping but distinct binding sites.

• Behavioral models. A single dose of 0.3 mg/kg reduced the total morphine-withdrawal score in rats by 39.6% and raised the tactile sensitivity threshold ninefold, against diazepam at 2 mg/kg as comparator.
• Combination behavior. Under unpredictable chronic mild stress, Selank plus diazepam was the most effective pairing in the elevated plus maze, while Selank alone was the most effective at reducing drug-induced anxiety in unstressed animals.
• Immune signaling. In a social-stress rat model, 100 µg/kg daily for 20 days reduced stress-driven elevations in IL-1β, IL-6, TNF-α and TGF-β1 and restored suppressed IL-4.

One structural caveat applies to all of it. These experiments are overwhelmingly from the institutes that developed the molecule, and several were given by injection rather than by nose — the morphine-withdrawal work was intraperitoneal. Mechanistic findings from an injected rat do not automatically describe what a nasal dose does in a person.

The measurement nobody has published

Here is the gap that route articles are supposed to name. For a compound whose defining feature is that it is given intranasally, there is no published figure for how much of a nasal dose of Selank reaches systemic circulation or the brain, in any species. No human pharmacokinetic study appears in the indexed literature.

What exists instead is indirect. The Panikratova imaging work shows a central effect after nasal dosing. Work on the same Russian family of peptides showed that intranasal administration of Semax altered BDNF and trkB messenger RNA in rat brain, which is a demonstration that this class can reach brain tissue by that route. And a serum study reported that Selank and Semax inhibit enkephalin-degrading enzymes, which is a proposed reason their effects outlast their measurable presence.

What a Selank spray is worth, and to whom

Our read is that Selank sits in an awkward middle that suits neither the enthusiasts nor the dismissers. It has more behind it than most of the compounds in this library: an approved indication somewhere in the world, a coherent mechanism, a placebo-controlled imaging study, and a preclinical record spanning behavior, cytokines and stress physiology. It also has zero Western randomized controlled trials, in any indication.

That gap is structural rather than damning. The molecule is long out of patent protection in any practical sense, the intellectual property sits with Russian institutions, and the anxiety market is already served by cheap generics with large trial bases. Nobody has a commercial reason to spend nine figures proving it.

• Formulation is not interchangeable. The Russian safety experience is for a manufactured nasal solution, at short courses of days to weeks. Long-term use is essentially unstudied.
• Dose cannot be derived from the literature. The rodent doses cited above are per kilogram and by injection; the Russian product's dosing is a pharmaceutical instruction, not a published protocol you can scale.
• Interactions are plausible and uncharacterized. The GABA-modulation finding is precisely the reason to expect interaction with benzodiazepines and alcohol, and precisely what has not been studied outside rodents.

Selank

Batch-matched COAHPLC + mass specResearch use only

Research-use-only material, sold by the vial with batch documentation. Check the certificate of analysis against the batch you receive.

Learn more

Frequently asked questions